Detecting Cancer While It Is Still Small Impacts Survival
the ONA take:
Detecting breast cancers when they are small still impacts survival despite the various effective therapies, a study published in The BMJ has shown.
Because breast cancer survival rates have significantly improved over the last few decades, mostly due to earlier diagnosis and more effective treatment options, traditional prognostic factors such as tumor size and number of positive lymph nodes are thought to no longer affect survival.
Therefore, researchers in the Netherlands sought to compare survival by tumor size and nodal status in patients with breast cancer during 1995 to 2005 with 2006 to 2012.
Researchers analyzed the overall survival data of 173,797 female patients with breast cancer. They found that tumors diagnosed during the 2006 to 2012 period were smaller, less likely to be lymph node positive, and more often low grade.
Patients with diagnoses during that time were also more likely to have undergone breast-conserving therapy, and the use of hormonal therapy, chemotherapy, and drug therapy were increased.
Results showed that relative survival rates and overall survival rates were higher for the 2006 to 2012 cohort for all tumor and nodal stages, particularly in women ages 75 years and older. The study demonstrated that both tumor stage and nodal status had a significant impact on overall survival in patients from both groups.
“Through public health screening and innovations in treatment, we are making steady progress against breast cancer,” the authors write. “A challenge ahead is to help other societies build models of screening and treatment that foster the access and success of the Dutch experience.”
Detecting breast cancers when they are small still impacts survival despite the various effective therapies.
Sign Up for Free e-newsletters
- Leukemia Risk in Children, Maternal Use of Hormonal Contraception Linked in Population Study
- Hodgkin Lymphoma Survivorship Marked by Periods of Actionable Distress
- Medication, Vaccination Uptake Improved by Involving Pharmacists in Elder Cancer Care
- Molecular Features May Predict Response in Primary Pancreatic Cancer
- Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
- Navigating Prostate Cancer: A Patient's Experience From Diagnosis to Survivor
- Cell Phones and Cancer Risk (Fact Sheet)
- How Likely Are Oncologists to Refer for Palliative Care? Depends on Their Age
- Use of Corticosteroids With PD-1 or PD-L1 Inhibitors Associated With Poorer Outcomes in NSCLC
- Chemoimmunotherapy Increases Survival in Triple-Negative Breast Cancer
- Integrative Medicine in Childhood Cancer: Practices That Can Help Pediatric Patients
- Clinical Characteristics That Increase Risk of Chemotherapy-Induced Febrile Neutropenia Identified
- Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
- Counseling Patients on Oral Chemotherapy
- Patients and Caregivers Worry About Cost of Cancer Care
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|